Grant of restricted share units
Filed with HKEX · Stock code 3696 · · 6 pages · English
Summary by 6ix AI
InSilico Medicine Cayman TopCo has announced the grant of restricted share units to eligible persons under its Post-IPO RSU Scheme. The grant aims to align the interests of the RSU Grantees with the company's long-term growth and to retain high-performing employees. After this grant, a significant number of shares will remain available for future grants under the equity incentive plans.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
InSilico Medicine Cayman TopCo on 6ix
Earlier from InSilico Medicine Cayman TopCo
- Voluntary announcement InSilico Medicine reports preliminary positive first-in-human clinical trial data for ISM6331 designed using generative AI in mesothelioma and other solid tumors at esmo 2026
- Voluntary announcement InSilico Medicine triggers a milestone payment in AI-driven R&D collaboration with Servier for achieving early drug discovery milestone
- Voluntary announcement InSilico Medicine nominates peripheral-restricted VAV1 molecular glue degrader for potential treatment of autoimmune diseases
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement InSilico Medicine nominates next-generation small molecule GIPR antagonist for potential intervention of obesity and related disorders
Later from InSilico Medicine Cayman TopCo
- Voluntary announcement on-market share repurchase
- Discloseable transaction participation in the establishment of an investment fund
Follow InSilico Medicine Cayman TopCo into a list and get an email when it puts out news.
Follow InSilico Medicine Cayman TopCo